A few bile acid analogs have functioned as FXR or TGR5 agonists (INT-767, WAY-362450) showing that they can reduce pro-inflammatory gene expression and increase monocyte and IL-10 production to improve hepatic inflammation, steatosis, and fibrosis [47,48]. This evidence concerns the gene NR1H4 and steatosis.